SAMSUNG PHARM Past Earnings Performance
Past criteria checks 0/6
There is insufficient data on SAMSUNG PHARM's performance over the last few years.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2019 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How SAMSUNG PHARM makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 19 | 44,654 | -5,959 | 15,580 | 181 |
| 30 Jun 19 | 31,797 | 1,102 | 10,753 | 181 |
| 31 Mar 19 | 45,154 | 3,125 | 13,704 | 267 |
| 31 Dec 18 | 46,484 | -2,076 | 12,709 | 378 |
| 30 Sep 18 | 42,642 | -362 | 12,514 | 1,081 |
| 30 Jun 18 | 42,541 | -2,754 | 11,780 | 1,081 |
| 31 Mar 18 | 40,990 | -5,994 | 11,324 | 994 |
| 31 Dec 17 | 41,919 | -7,274 | 11,273 | 939 |
| 30 Sep 17 | 45,984 | -11,062 | 8,476 | 738 |
| 30 Jun 17 | 48,365 | -13,881 | 10,059 | 789 |
| 31 Mar 17 | 47,112 | -16,135 | 12,245 | 831 |
| 31 Dec 16 | 47,194 | -17,218 | 12,565 | 899 |
| 30 Sep 16 | 50,072 | -12,224 | 15,461 | 482 |
| 30 Jun 16 | 47,103 | -12,167 | 14,546 | 432 |
| 31 Mar 16 | 45,851 | -3,548 | 12,651 | 421 |
| 31 Dec 15 | 42,165 | -994 | 12,111 | 297 |
| 30 Sep 15 | 35,366 | -18,494 | 29,179 | 123 |
| 30 Jun 15 | 30,909 | -15,432 | 27,399 | 124 |
| 31 Dec 14 | 30,288 | -23,748 | 27,878 | 6 |
Quality Earnings: Insufficient data to determine if A001360 has high quality earnings.
Growing Profit Margin: Insufficient data to determine if A001360's profit margins have improved over the past year.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if A001360's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare A001360's past year earnings growth to its 5-year average.
Earnings vs Industry: Insufficient data to determine if A001360's earnings growth over the past year exceeded the Pharmaceuticals industry average.
Return on Equity
High ROE: A001360 has a negative Return on Equity (0%), as it is currently unprofitable.